Reply to &quot;Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis&quot;.

Saphnelo (anifrolumab-fnia) - AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/42788326

Catharina Lindholm; David Jayne; Joachim Almquist; Lynn Bertagnolli; Raj Tummala; Weifeng Tang; Yen Lin Chia

Sep 26, 2026